Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors

Trial Profile

A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Genolimzumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors CBT Pharmaceuticals
  • Most Recent Events

    • 09 Sep 2018 Planned number of patients changed from 50 to 114.
    • 09 Sep 2018 Planned End Date changed from 1 Mar 2019 to 1 Dec 2021.
    • 09 Sep 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top